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Abstract 
Background: There is increasing concern regarding cardiovascular risk in individuals with non‑alcoholic fatty liver 
disease. This study was conducted to evaluate whether hepatic steatosis with or without fibrosis is associated with the 
progression of carotid atherosclerosis in patients with type 2 diabetes.
Methods: From a longitudinal cohort, we enrolled 1120 patients with type 2 diabetes who underwent repeated 
carotid artery ultrasonography every 1–2 years. Ultrasonographic findings at baseline and after 6–8 years were com‑
pared. Presence of hepatic steatosis was mainly assessed by abdominal ultrasonography; patients with hepatic steato‑
sis were further evaluated for hepatic fibrosis according to fibrosis‑4 index. We investigated the association between 
liver status and atherosclerosis progression.
Results: Of 1120 patients, 636 (56.8%) were classified as having hepatic steatosis at baseline. After 6–8 years, 431 
(38.5%) showed atherosclerosis progression. Hepatic steatosis was significantly associated with atherosclerosis 
progression (adjusted odds ratio[AOR]: 1.370, 95% CI 1.025–1.832; p < 0.05). Among patients with hepatic steatosis, 
only individuals with fibrosis showed significant association with atherosclerosis progression (AOR: 1.615, 95% CI 
1.005–2.598; p < 0.05). The association between hepatic fibrosis and atherosclerosis progression was significant in all 
metabolic subgroups regardless of age, body mass index, presence of metabolic syndrome, or insulin sensitivity (all 
p < 0.05). Furthermore, subjects with hepatic steatosis & fibrosis and ≥ 4 components of metabolic syndrome criteria 
showed markedly increased risk of atherosclerosis progression (AOR: 2.430, 95% CI 1.087–5.458; p < 0.05).
Conclusions: Hepatic steatosis with fibrosis is independently associated with the progression of carotid atherosclero‑
sis in patients with type 2 diabetes.
Keywords: Atherosclerosis, Hepatic fibrosis, Metabolic syndrome, Non‑alcoholic fatty liver disease, Non‑alcoholic 
steatohepatitis, Type 2 diabetes
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Background
The prevalence of non-alcoholic fatty liver disease 
(NAFLD) is rapidly rising relative to increased obe-
sity and/or type 2 diabetes [1]. NAFLD is known to be 
associated with various complications, such as chronic 
kidney disease (CKD), cancer, heart failure, or athero-
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the leading cause of mortality for patients with NAFLD 
[3–7]. Non-alcoholic steatohepatitis (NASH), one of sev-
eral categories of NAFLD which is characterized by lobu-
lar inflammation and hepatocyte ballooning, produces 
more significant liver injury like fibrosis or cirrhosis 
compared to simple NAFLD [8], and patients with NASH 
were reported to have much higher incidence of coronary 
artery disease-related mortality [9–11]. In this aspect, 
there had been numerous previous studies investigat-
ing the causal relationship between NAFLD/NASH and 
carotid atherosclerosis [12–15], regarding carotid ather-
osclerosis as a surrogate marker of coronary atheroscle-
rosis. Therefore, it might be important to assess hepatic 
steatosis and fibrosis to identify those at high risk of car-
diovascular disease, and to optimally commence medical 
interventions [16, 17].
This scenario is of special concern in patients with type 
2 diabetes, which is known to be associated with higher 
risk of NAFLD [16, 18]. While NAFLD is an independent 
risk factor for cardiovascular complications [19], when 
combined with type 2 diabetes, it further increases the 
risk of systemic atherosclerosis [3]. Insulin resistance, a 
characteristic feature of both type 2 diabetes and NAFLD, 
is known as the key pathophysiology linking type 2 dia-
betes, NAFLD, and atherosclerosis [2, 20]. However, lit-
tle is known about the longitudinal effects of NAFLD or 
NASH on systemic atherosclerosis in type 2 diabetes.
The aim of this study was to investigate the relationship 
between NAFLD with or without significant fibrosis and 
the risk of carotid atherosclerosis progression assessed by 




Participants were recruited from the Seoul Metabolic 
Syndrome Cohort, of which total 13,296 patients were 
diagnosed and treated for type 2 diabetes from Novem-
ber 1997 to September 2016 at Huh Diabetes Center as 
previously described [3, 21]. Patients aged 19  years or 
older who had undergone repeated carotid artery ultra-
sonography at 1–2-year intervals for up to 6-8 years were 
enrolled. Participants were diagnosed with type 2 diabe-
tes according to the American Diabetes Association clas-
sification [22]. Patients were excluded for any one of the 
following criteria: (1) under 19 years of age; (2) diagnosed 
with type 1 diabetes; (3) pregnant; (4) diagnosed with 
liver disease other than NAFLD, such as viral or auto-
immune hepatitis; and (5) history of heavy alcohol con-
sumption (> 140 g/week). Patients with baseline bilateral 
carotid artery plaque in whom occurrence of new-onset 
plaque was difficult to judge in repeat ultrasonography 
were also excluded. In total, we enrolled 1120 patients 
with type 2 diabetes who underwent repeat carotid artery 
ultrasonography at 1–2-year intervals for up to 6–8 years 
and evaluations for the presence of hepatic steatosis or 
fibrosis at baseline. All participants provided written 
informed consent, and the Ethics Committee of the Yon-
sei University College of Medicine approved this study 
(4-2019-0270).
Measurements and definitions of clinical and laboratory 
parameters
At baseline, we collected information from participants 
regarding their medical and family history, smoking and 
alcohol history/consumption, and physical activity level 
per week. Medication history regarding aspirin, statin, 
and anti-diabetic drug (insulin, sulfonylurea, metformin, 
thiazolidinedione) usage was also reviewed. Anthropo-
metrics including weight, height, and waist circumfer-
ence were obtained by trained nurses who were blinded 
to patients’ clinical and laboratory data, and blood sam-
ples were collected from participants (a) after ≥ 8  h of 
fasting, and (b) 2  h after a meal. Metabolic parameters 
including HbA1c, lipid profiles (total cholesterol, high-
density lipoprotein cholesterol (HDL-C), low-density 
lipoprotein cholesterol (LDL-C), triglyceride), blood 
urea nitrogen (BUN), creatinine, total bilirubin, aspar-
tate/alanine aminotransferase (AST/ALT), total protein, 
albumin, and platelet count were measured by routine 
laboratory methods on fresh samples at the same day of 
collection.
The estimated glomerular filtration rate (eGFR) was 
derived from the Modification of the Diet in Renal Dis-
ease equation (MDRD) [23]. Diagnosis and classification 
of CKD was based on the Kidney Disease: Improving 
Global Outcomes (KDIGO) guidelines, and patients with 
eGFR < 60  mL/min/1.73  m2 for > 3  months were diag-
nosed as CKD stage III–V accordingly [24].
Insulin sensitivity was assessed by calculating the rate 
constant for plasma glucose disappearance (KITT; %/
min) in a short insulin tolerance test [25]. The test was 
performed at 8:00AM after an overnight fast, and venous 
blood samples were collected at 0, 3, 6, 9, 12, and 15 min 
after an intravenous bolus injection of regular insulin 
(Humulin; Eli Lilly, Indianapolis, IN, USA) at a dosage 
of 0.1 U/kg. Plasma glucose concentrations were meas-
ured immediately after sampling using Beckman glucose 
analyzer II (Beckman Coulter Inc., Brea, CA, USA), and 
KITT was determined by calculating the rate of the fall in 
log-transformed plasma glucose between 3 and 15  min. 
To prevent potential hypoglycemia, 100 mL of 20% dex-
trose solution was administered intravenously imme-
diately after testing. Insulin resistance was defined as 
KITT < 2.5%/min [26].
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The diagnosis of metabolic syndrome was made 
according to a joint interim statement of the Interna-
tional Diabetes Federation Task Force on Epidemiol-
ogy and Prevention; National Heart, Lung, and Blood 
Institute; American Heart Association; World Heart 
Federation; International Atherosclerosis Society; and 
International Association for the Study of Obesity pub-
lished in 2009 [27]. Hypertension was defined as sys-
tolic blood pressure (BP) ≥ 140 mmHg and/or a diastolic 
BP ≥ 90 mmHg, or current use of antihypertensive medi-
cations. Individuals who drank twice a month or more 
were defined as regular alcohol consumers, and partici-
pants who had ever smoked more than five packs of ciga-
rettes were considered ever-smokers. Regular exercise 
was defined as moderate to vigorous physical activity for 
over 30  min more than once a month. Overweight was 
defined as body mass index (BMI) ≥ 23 kg/m2 according 
to scientific statement from the World Health Organiza-
tion [28].
Liver status measurements
Among 1120 participants, 1086 underwent abdominal 
ultrasonography (iU22; Philips Healthcare, Andover, 
MA, USA) with a 3.5-MHz transducer after 8 h of fast-
ing. Ultrasound examinations were performed by trained 
radiologists who were blinded to the patients’ clinical 
and laboratory information. According to ultrasono-
graphic findings, participants were assessed on whether 
or not they had hepatic steatosis. The presence of hepatic 
steatosis in 34 patients who did not undergo abdomi-
nal ultrasonography was determined by calculating the 
Comprehensive Non-Alcoholic Fatty Liver Disease Score 
(CNS) [29], in which a score ≥ 40 indicated hepatic stea-
tosis. Those with hepatic steatosis were further evaluated 
for the presence of independent hepatic fibrosis by calcu-
lating the fibrosis-4 (FIB-4) index. Significant fibrosis was 
defined as FIB-4 index ≥ 1.45 in this study [30].
Carotid atherosclerosis measurements
Every participant underwent repeated carotid ultra-
sonography every 1–2  years to evaluate carotid athero-
sclerosis status. We compared the rate of atherosclerosis 
progression at baseline and at 6–8 years. Both common 
carotid arteries were examined by high-resolution ultra-
sonography (LOGIQ7; GE Healthcare, Chicago, IL, USA) 
by trained technicians who were blinded to the patients’ 
clinical and laboratory data. The mid and distal common 
carotid artery was scanned by lateral longitudinal projec-
tion, and carotid intima-media thickness (IMT; mm) was 
measured at three points: far wall of mid; distal common 
carotid artery; and 1  cm proximal to the carotid bulb. 
Carotid IMT was defined as the distance between lumen-
intima interface and media-adventitia interface, of which 
the mean value of three measurements on each side was 
used to represent carotid atherosclerosis status.
Carotid atherosclerosis progression was defined as the 
appearance of newly developed carotid plaque lesions on 
repeat ultrasonography. The presence of carotid plaque 
was defined as meeting any one of the following criteria: 
(1) carotid IMT of 1.5  mm or higher; (2) protrusion of 
atherosclerosis into the lumen of artery with ≥ 50% thick-
ness compared to the surrounding area; and (3) presence 
of distinct area of hyperechogenicity [31].
Statistical analysis
Baseline characteristics of study participants were ana-
lyzed according to liver status: no steatosis; steatosis only; 
and steatosis with fibrosis. Continuous variables were 
expressed as mean ± standard deviation (SD) and ana-
lyzed with one-way ANOVA for intergroup comparison, 
followed by Bonferroni test or Dunn procedure for post 
hoc analysis. All categorical variables were expressed as 
number (proportion) and compared by Chi square test.
We performed multivariable logistic regression analy-
sis to calculate odds ratio (OR) of carotid atherosclerosis 
progression according to the presence of hepatic steato-
sis. After subdividing patients with hepatic steatosis into 
steatosis only and steatosis with fibrosis, Chi square test 
was performed to compare the proportion of carotid ath-
erosclerosis progression in each liver status subgroup (no 
steatosis, steatosis only, and steatosis with fibrosis).
To verify independent association between liver status 
and carotid atherosclerosis progression, we performed 
multivariable logistic regression analysis in which various 
confounding factors were adjusted in a stepwise man-
ner: age and gender were adjusted in Model 2; duration 
of diabetes, HbA1c, LDL-cholesterol, HDL-cholesterol, 
statin use, alcohol/smoking consumption, exercise status, 
systolic BP, diastolic BP, KITT and CKD stage III-V were 
adjusted in Model 3; and BMI was adjusted in model 4. 
Models 5 and 6 were built by further adjusting Model 
4 with waist circumference and follow-up duration, 
respectively.
Also, logistic regression analysis was performed to 
detect the association between liver status and carotid 
atherosclerosis progression after dividing patients into 
two subgroups by age (70 years), BMI (overweight status: 
23.0  kg/m2), presence of metabolic syndrome, or KITT 
(2.5%/min). Cut-off for age was chosen according to the 
previous report that cytochrome P450 level declines sig-
nificantly after age 70 [32], which is known to be very 
closely related to cholesterol homeostasis and athero-
sclerosis [33–35]. Finally, study participants were divided 
into nine subgroups according to liver status and meta-
bolic syndrome criteria, and multivariable logistic regres-
sion analysis was performed to calculate OR of carotid 
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atherosclerosis progression in each subgroup. p val-
ues < 0.05 were considered statistically significant, and all 
statistical analyses were performed using R version 4.0.0 
(R Foundation for Statistical Computing, Vienna, Aus-
tria) and IBM SPSS Statistics version 24.0 (IBM Corp., 
Armonk, NY, USA).
Results
Baseline characteristics of study participants
Baseline characteristics are summarized in Table  1. Of 
1120 participants, 636 (56.8%) had hepatic steatosis; 
among them, 222 (19.8%) had significant fibrosis.
The mean age of subjects with hepatic steatosis and 
fibrosis was 59.8 (± 7.8) years, which was significantly 
higher compared to the other subgroups (p < 0.001). BMI 
(kg/m2) was higher in those with both hepatic steatosis 
and fibrosis (26.1 ± 3.2) or only steatosis (25.6 ± 3.0) com-
pared to those without steatosis (23.2 ± 2.8) (p < 0.001). 
282 (69.8%) participants with only hepatic steatosis and 
150 (67.9%) participants with both hepatic steatosis and 
fibrosis had metabolic syndrome, while only 174 (37.3%) 
participants had metabolic syndrome among those with-
out hepatic steatosis (p < 0.001). KITT (%/min) was 2.4 
(± 1.0) in subjects with no hepatic steatosis, which was 
significantly higher compared to the subgroup with only 
steatosis (1.9 ± 0.8) or with both steatosis and fibrosis 
(1.8 ± 0.7) (p < 0.001), indicating that participants without 
hepatic steatosis were more insulin-sensitive than those 
in other two subgroups.
Participants with both steatosis and fibrosis showed 
lower eGFR (88.0 ± 27.4) compared to those with no 
steatosis (94.5 ± 30.9) (p = 0.018), but it was not signifi-
cantly lower than the steatosis only group (93.0 ± 28.0) 
(p = 0.122). There was no significant difference by sex or 
statin use between the three subgroups.
The mean carotid IMTs (mm) at baseline were 
0.75 ± 0.15, 0.76 ± 0.15, and 0.81 ± 0.14 in patients with 
no hepatic steatosis, steatosis only, and steatosis with 
fibrosis, respectively (p < 0.001). The proportion of par-
ticipants with carotid plaque at baseline was not signifi-
cantly different between the three subgroups (p = 0.365).
Association between hepatic steatosis and progression 
of carotid atherosclerosis
The presence of hepatic steatosis increased the risk of 
carotid plaque progression (OR: 1.368, 95% CI 1.071–
1.748; p = 0.012). This result persisted after adjusting 
for age, gender, systolic BP, diastolic BP, duration of dia-
betes, HbA1c, KITT, CKD stage III-V, total cholesterol, 
statin use, and alcohol history (adjusted odds ratio[AOR]: 
1.370, 95% CI 1.025–1.832; p = 0.034) (Fig. 1).
Presence of hepatic fibrosis and carotid atherosclerosis 
progression in patients with NAFLD
The number (%) of patients with carotid plaque progres-
sion after 6–8  years was 166 (34.3%), 157 (37.9%), and 
108 (48.6%), respectively, among those with no hepatic 
steatosis, steatosis only, and steatosis with fibrosis. The 
difference was statistically significant (p = 0.001) (Fig. 2).
To further investigate whether presence of hepatic 
fibrosis is independently associated with the progression 
of carotid plaque in patients with NAFLD, we performed 
multivariable logistic regression analyses in a stepwise 
manner. With no adjustment (Model 1), hepatic steatosis 
with fibrosis was statistically significantly associated with 
carotid plaque progression (OR: 1.815, 95% CI 1.314–
2.507; p < 0.001), whereas steatosis only was not signifi-
cant (OR: 1.170, 95% CI 0.891–1.538; p = 0.259). Steatosis 
with fibrosis was still significantly associated with carotid 
plaque progression after adjusting for age, gender (Model 
2. AOR: 1.494, 95% CI 1.071–2.084; p = 0.018), duration 
of diabetes, HbA1c, LDL-cholesterol, HDL-cholesterol, 
statin use, alcohol/smoking consumption, exercise status, 
systolic BP, diastolic BP, KITT, CKD stage III-V (Model 3. 
AOR: 1.740, 95% CI: 1.111-2.723; p = 0.015), BMI (Model 
4. AOR: 1.636, 95% CI 1.024–2.612; p = 0.039), and waist 
circumference (Model 5. AOR: 1.615, 95% CI 1.005–
2.598; p = 0.048). Further adjusting Model 4 for follow-
up duration still did not alter statistical significance of 
the result (Model 6. AOR: 1.606, 95% CI 1.004–2.572; 
p = 0.048) (Fig. 3).
Risk of carotid atherosclerosis progression according 
to metabolic profiles
To examine the presence of potential effect modification, 
we analyzed the risk of carotid atherosclerosis progres-
sion according to several metabolic factors. Overall, the 
analysis showed no difference between metabolic sub-
groups, whether they were divided by age, BMI, presence 
of metabolic syndrome, or insulin resistance (all p inter-
action > 0.05). In detail, hepatic steatosis without fibrosis 
was not associated with the progression of carotid ather-
osclerosis in any metabolic subgroup. However, patients 
with combined hepatic steatosis & fibrosis showed statis-
tically significantly higher risk of carotid atherosclerosis 
progression regardless of age (OR: 3.683, 95% CI 1.036–
13.100 in subgroup with age ≥ 70; OR: 1.653, 95% CI 
1.178–2.321 in subgroup with age < 70), BMI (OR: 1.531, 
95% CI 1.027–2.283 in subgroup with BMI ≥ 23; OR: 
2.480, 95% CI 1.113–5.527 in subgroup with BMI < 23), 
presence of metabolic syndrome (OR: 1.636, 95% CI 
1.051–2.548 in subgroup with metabolic syndrome; OR: 
1.784, 95% CI 1.051–3.026 in subgroup without meta-
bolic syndrome), or insulin sensitivity (OR: 1.712, 95% CI 
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1.164–2.518 in subgroup with KITT < 2.5 (insulin resist-
ant); OR: 1.972, 95% CI: 1.011-3.847 in subgroup with 
KITT ≥ 2.5 (insulin sensitive)). There was no effect modi-
fication by metabolic factors (p interaction = 0.224, 0.258, 
0.815, and 0.889 for age, BMI, presence of metabolic syn-
drome, and insulin sensitivity, respectively) (Fig. 4).
Consecutively, to investigate the combinatorial 
effects of cardiometabolic risk factors and liver status, 
Table 1 Baseline Characteristics
Variables are shown as mean ± SD or n (%). ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; DBP, 
diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; IMT, intima-media thickness; KITT, rate constant for 
plasma glucose disappearance; LDL-C, low-density lipoprotein cholesterol; MDRD, modification of diet in renal disease equation; SBP, systolic blood pressure; SD, 
standard deviation; SU, sulfonylurea; TZD, thiazolidinedione
a  p values < 0.05 versus no steatosis
b  p values < 0.05 versus steatosis only
Study population No steatosis Steatosis only Steatosis with fibrosis p value
N = 1120 N = 484 N = 414 N = 222
Age, years 55.4 ± 9.4 52.4 ± 9.7a 59.8 ± 7.8ab < 0.001
Male, n (%) 216 (44.6%) 211 (51.0%) 104 (46.8%) 0.163
Weight, kg 61.1 ± 9.4 68.8 ± 11.8a 68.8 ± 10.7a < 0.001
Height, cm 162.1 ± 8.6 163.6 ± 8.9a 162.4 ± 8.5 0.033
BMI, kg/m2 23.2 ± 2.8 25.6 ± 3.0a 26.1 ± 3.2a < 0.001
Waist Circumference, cm 79.2 ± 7.5 85.8 ± 8.0a 87.2 ± 7.8a < 0.001
Metabolic Syndrome, n/total n (%) 174/466 (37.3%) 282/404 (69.8%) 150/221 (67.9%) < 0.001
Regular alcohol consumption, n/total n (%) 182/437 (41.6%) 183/392 (46.7%) 70/204 (34.3%) 0.014
Smoking, ever, n/total n (%) 166/420 (39.5%) 174/384 (45.3%) 70/194 (36.1%) 0.072
Regular exercise, n/total n (%) 135/383 (35.2%) 172/360 (47.8%) 78/187 (41.7%) 0.002
Hypertension, n (%) 130 (26.9%) 135 (32.6%) 97 (43.7%) < 0.001
SBP, mmHg 131.1 ± 16.7 135.0 ± 16.9a 138.3 ± 16.4a < 0.001
DBP, mmHg 84.3 ± 10.6 88.3 ± 11.2a 87.4 ± 10.6a < 0.001
Duration of diabetes, years 7.2 ± 6.9 5.5 ± 5.3a 6.1 ± 5.5 < 0.001
HbA1c, % 8.3 ± 2.1 8.7 ± 1.9a 8.0 ± 1.6b < 0.001
HbA1c, mmol/mol 67.0 ± 23.0 72.0 ± 20.8a 64.0 ± 17.5b < 0.001
KITT, %/min 2.4 ± 1.0 1.9 ± 0.8a 1.8 ± 0.7a < 0.001
Total Cholesterol, mg/dL 188.6 ± 38.5 201.8 ± 45.1a 197.7 ± 39.3a < 0.001
Triglyceride, mg/dL 115.7 ± 63.3 172.3 ± 140.0a 157.7 ± 89.2a < 0.001
HDL‑C, mg/dL 54.2 ± 14.8 48.4 ± 12.2a 50.6 ± 12.8a < 0.001
LDL‑C, mg/dL 110.1 ± 32.3 118.9 ± 35.7a 113.6 ± 35.3 0.002
BUN, mg/dL 17.5 ± 7.3 16.9 ± 5.0 18.7 ± 8.2b 0.005
Creatinine, mg/dL 0.8 ± 0.2 0.8 ± 0.3 0.8 ± 0.2a 0.007
eGFR (MDRD), mL/min/1.73 m2 94.5 ± 30.9 93.0 ± 28.0 88.0 ± 27.4a 0.022
Total Bilirubin, mg/dL 0.9 ± 0.3 0.8 ± 0.3 1.0 ± 0.5ab 0.002
AST, IU/L 25.0 ± 12.6 24.4 ± 8.0 36.7 ± 17.6ab < 0.001
ALT, IU/L 23.6 ± 15.9 30.5 ± 14.9a 37.0 ± 25.2ab < 0.001
Total Protein, mg/dL 7.3 ± 0.4 7.3 ± 0.4 7.4 ± 0.5ab 0.006
Albumin, mg/dL 4.3 ± 0.4 4.4 ± 0.3 4.4 ± 0.3 0.068
Platelet,/uL 210.7 ± 59.2 240.0 ± 53.4a 183.3 ± 38.6ab < 0.001
Insulin use, n (%) 47 (9.7%) 24 (5.8%) 15 (6.8%) 0.076
SU use, n (%) 240 (49.6%) 191 (46.1%) 140 (63.1%) < 0.001
Metformin use, n (%) 172 (35.5%) 156 (37.7%) 93 (41.9%) 0.270
TZD use, n (%) 57 (11.8%) 25 (6.0%) 21 (9.5%) 0.012
Statin use, n (%) 63 (13.0%) 53 (12.8%) 25 (11.3%) 0.797
Aspirin use, n (%) 62 (12.8%) 58 (14.0%) 35 (15.8%) 0.568
Carotid IMT, mm 0.75 ± 0.15 0.76 ± 0.15 0.81 ± 0.14ab < 0.001
Presence of plaque, n (%) 153 (31.6%) 127 (30.7%) 80 (36.0%) 0.365
Page 6 of 11Lee et al. Cardiovasc Diabetol           (2020) 19:81 
participants were divided into 9 subgroups according 
to liver status (no steatosis, steatosis only, steatosis with 
fibrosis) and the number of metabolic syndrome criteria 
met (0–2, 3, 4–5). In each metabolic syndrome criteria 
subgroup, the risk of carotid atherosclerosis progression 
was generally higher in subjects with hepatic steatosis, 
and far higher in those with both hepatic steatosis and 
fibrosis. Similarly, in each liver status subgroup, a higher 
number of metabolic syndrome criteria generally corre-
lated with higher risk of carotid atherosclerosis progres-
sion. Compared to those with 0–2 metabolic syndrome 
criteria and no hepatic steatosis, subjects with 4–5 met-
abolic syndrome criteria and both steatosis and fibrosis 
were at significantly higher risk of carotid atherosclerosis 
progression (AOR: 2.430, 95% CI 1.087–5.458, p = 0.031) 
(Fig. 5).
Discussion
Principal findings and clinical implications
Ultrasonography is now widely accepted as a useful 
screening tool to detect carotid artery plaque and pre-
dict cardiovascular events [31, 36]. With serial carotid 
ultrasonography of patients with type 2 diabetes at 1–2-
year intervals for up to 6–8  years, this study demon-
strated that hepatic steatosis with significant fibrosis was 
strongly associated with the progression of carotid artery 
atherosclerosis, even in relatively metabolically-healthy 
patients. Our results have also shown that hepatic fibro-
sis and metabolic syndrome accelerate atherosclerosis 
progression independently of each other, delivering an 
additive effect when combined together.
Based on these findings, we suggest that hepatic fibro-
sis can be an independent risk factor for atherogenesis 
acceleration, and its identification by clinical indicators 
may be helpful to predict the risk of atherosclerosis pro-
gression. Also, patients who are already diagnosed 
with metabolic syndrome should especially be aware of 
hepatic fibrosis to blunt profoundly higher risk of ath-
erosclerosis produced by the combined effect of hepatic 
fibrosis and metabolic syndrome.
Results in relation to other studies
NAFLD is considered a ‘hepatic manifestation of meta-
bolic syndrome’. It is very closely related to type 2 
diabetes or metabolic syndrome, and the main patho-
physiology underlying this relationship is known to be 
insulin resistance [37, 38]. The association is considerably 
strong that NAFLD is present even in obese adolescents 
with dysglycemia [39]. NAFLD and metabolic syndrome 
can be considered to have similar effects on arteries, 
which accelerate atherogenesis via inflammation [40, 41], 
increased oxidative stress [42], atherogenic dyslipidemia 
[43], imbalance of adipokines [44], and hypercoagulable 
status [45]. As a result, NAFLD patients present lower 
reactive hyperemia index and higher pulse wave velocity 
Fig. 1 Progression of Carotid Atherosclerosis by Presence of Hepatic 
Steatosis. Odds ratio of carotid atherosclerosis progression according 
to the presence of hepatic steatosis. The result is adjusted for age, 
gender, systolic blood pressure, diastolic blood pressure, duration 
of diabetes, HbA1c, rate constant for plasma glucose disappearance 
(KITT), chronic kidney disease stage III–V, total cholesterol, statin 
use, and alcohol history. Levels of significance: ap = 0.012 (crude); 
bp = 0.034 (adjusted) (Logistic regression analysis)
Fig. 2 Progression of Carotid Atherosclerosis by Presence of Hepatic Steatosis and Fibrosis. Proportion of carotid atherosclerosis progression in 
patients with no steatosis, steatosis only, and steatosis with fibrosis. Levels of significance: p = 0.001 (Chi square test)
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[46], and NAFLD can serve as a strong predictor of coro-
nary artery calcification in metabolically healthy subjects 
[47].
In consequence, NAFLD was reported as an independ-
ent risk factor for cardiovascular disease in the general 
population [7, 48]. After several efforts to prove this rela-
tionship via carotid ultrasonography, it was discovered 
that NAFLD was significantly associated with carotid 
stenosis in Chinese population [49], increased carotid 
IMT in type 2 diabetes patients with insulin resistance 
[3], and higher prevalence of carotid plaque [14]. More-
over, NAFLD was shown to be associated with higher 
cardiovascular risk in terms of carotid IMT and dyslipi-
demia even in nondiabetic patients [50]. In the present 
study, we focused on the long-term effect of NAFLD 
with or without significant fibrosis on atherosclerosis by 
repeated carotid ultrasonography. The results showed 
that progression of carotid atherosclerosis after 6-8 years 
occurred more frequently in patients with NASH. 
Although it has been shown that visceral obesity is asso-
ciated with cardiometabolic comorbidities of type 2 dia-
betes, NAFLD, or atherosclerotic cardiovascular diseases 
[51], further adjustment for waist circumference along 
with other common metabolic factors did not alter the 
significance of association between hepatic fibrosis and 
atherosclerosis progression in our analysis.
To our knowledge, this is the first report to demon-
strate that hepatic fibrosis is significantly associated with 
the progression of carotid artery atherosclerosis in sub-
jects with type 2 diabetes. It indicates that not only pres-
ence—but also severity—of metabolic liver disease can 
affect the risk of cardiovascular complications. Previous 
long-term studies showed that risk of coronary artery 
disease-related mortality was much higher in patients 
with NASH (12–16%) [9, 52] compared to NAFLD 
(1–3%) [10, 53], and these findings were consistent with 
a recent meta-analysis in which increased NAFLD sever-
ity produced higher risk of cardiovascular complications 
[11], or recent large Korean population-based cohort 
study which demonstrated the linear association between 
fatty liver index (FLI) and major adverse cardiovascular 
events [54]. Altered lipidomics and increased hepatic 
production of prothrombogenic factors, including fetuin-
A in patients with fibrosing NASH, can be potential con-
tributors to the link between NASH and cardiovascular 
diseases [55].
In addition, the association between hepatic fibrosis 
and risk of atherosclerosis progression was significant in 
all metabolic subgroups regardless of age, BMI, presence 
of metabolic syndrome, or insulin sensitivity. It indicates 
that hepatic fibrosis may serve as a predictive marker for 
increased susceptibility to atherosclerosis progression 
even with less evidence of systemic metabolic alterations, 
implicating the possible presence of systemic profibro-
genic stimuli that accelerate atherogenesis in patients 
with hepatic fibrosis [56].
Conversely, there was no incremental risk of ath-
erosclerosis progression in hepatic steatosis without 
fibrosis in type 2 diabetes patients. This finding was 
similar to that of a previous study in which patients with 
hepatic steatosis and no additional feature of liver injury 
were found to follow a relatively benign clinical course, 
with mortality similar to the general population [57]. 
Although steatosis without fibrosis was not associated 
with increased risk of atherosclerosis progression in this 
study, repeat ultrasonography was not performed beyond 
Fig. 3 Risk of Carotid Atherosclerosis Progression According to Hepatic Status. Odds ratios of carotid atherosclerosis progression according to 
hepatic status. Model 1 = Crude model without any adjustment; Model 2 = Model 1 + age, gender; Model 3 = Model 2 + duration of diabetes, 
HbA1c, low‑density lipoprotein cholesterol, high‑density lipoprotein cholesterol, statin use, alcohol/smoking consumption, exercise status, systolic 
blood pressure, diastolic blood pressure, rate constant for plasma glucose disappearance (KITT), chronic kidney disease stage III‑V; Model 4 = Model 
3 + body mass index; Model 5 = Model 4 + waist circumference; Model 6 = Model 4 + follow‑up duration. (Logistic regression analysis)
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8  years, making it difficult to predict longer-term effect 
of steatosis without fibrosis on the risk of atherosclero-
sis progression. Since high rates of fibrosis progression 
have been demonstrated in patients with steatosis [58], 
it would be important to consider its clinical significance 
and to manage it appropriately without overlooking the 
risk of cardiovascular complication.
Strengths & limits
This study has several distinguishing strengths. First, we 
analyzed long-term results of carotid ultrasonography 
in subjects with type 2 diabetes. Most previous studies 
using carotid ultrasonography were cross-sectional and 
insufficient to determine a causal relationship. In addi-
tion, since this study was a hospital-based cohort study 
conducted at a single institution, the participants were 
managed and evaluated under standardized conditions 
and practices.
A major limitation of this study is the fact that a bio-
chemical scoring system, rather than liver biopsy, was 
used to evaluate hepatic fibrosis, which is currently not 
a gold-standard for the diagnosis. However, FIB-4 index 
was initially validated by comparing the results to that 
of liver biopsy [30], and they were shown to have fairly 
high accuracy to predict hepatic fibrosis [59, 60]. Sec-
ondly, this study analyzed the findings of carotid deterio-
ration using ultrasonography, one of the major surrogate 
markers of cardiovascular disease. However, our meth-
ods did not allow for the investigation of cardiovascular 
events that could represent a direct outcome of athero-
sclerosis progression. Also, antiplatelet, antihyperglyce-
mic agent, or fibric acid usage were not adjusted in our 
models, which are potential confounding factors that 
Fig. 4 Hepatic Status and Carotid Atherosclerosis Progression by Metabolic Confounders. Odds ratios of carotid atherosclerosis progression 
according to hepatic status and a Age. Level of significance: p interaction = 0.224. b Body mass index. Level of significance: p interaction = 0.258. 
c Presence of metabolic syndrome. Level of significance: p interaction = 0.815. d Insulin sensitivity. Level of significance: p interaction = 0.889. Risk 
estimates were calculated in each subgroup using patients with no steatosis as a reference (Logistic regression analysis). BMI, body mass index; KITT, 
rate constant for plasma glucose disappearance
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could influence our results. In addition, we did not con-
sider how participants’ metabolic factors changed over 
time in our analyses. Finally, this study was based on a 
single-center cohort of Koreans with a relatively small 
number of participants. Therefore, further larger studies 
including other ethnic populations are needed to validate 
the results, as well as to confirm generalizability of the 
results.
Conclusions
In conclusion, hepatic steatosis with significant fibro-
sis was independently associated with the progression 
of carotid atherosclerosis in patients with type 2 diabe-
tes. The association was still significant in subgroups of 
patients who were metabolically healthy, and it became 
more prominent relative to criteria for metabolic syn-
drome. Identification of hepatic steatosis with significant 
fibrosis may be helpful to predict and prevent the risk 
of atherosclerosis progression in individuals with type 2 
diabetes.
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